source
- Alphabet’s GV tops biotech corporate investors with $5.23 billion in deals since 2025Alphabet’s venture arm GV has become the largest corporate spender in biotech, investing a cumulative $5.23 billion across 20 deals since the start of 2025. The total outlay exceeds the combined v…
- Aspen Neuroscience and Bambusa Therapeutics each target $134 million IPOsAspen Neuroscience, a cell‑therapy company focused on Parkinson's disease, and Bambusa Therapeutics, a bispecific biotech, have filed SEC documents outlining plans for initial public offerings. Bo…